Literature DB >> 29974072

The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin.

Xiaoli Huang1, Björn Borgström2, John Stegmayr1,3, Yasmin Abassi4, Monika Kruszyk2, Hakon Leffler3, Lo Persson5, Sebastian Albinsson5, Ramin Massoumi4, Ivan G Scheblykin6, Cecilia Hegardt7, Stina Oredsson1, Daniel Strand2.   

Abstract

Tumors are phenotypically heterogeneous and include subpopulations of cancer cells with stemlike properties. The natural product salinomycin, a K+-selective ionophore, was recently found to exert selectivity against such cancer stem cells. This selective effect is thought to be due to inhibition of the Wnt signaling pathway, but the mechanistic basis remains unclear. Here, we develop a functionally competent fluorescent conjugate of salinomycin to investigate the molecular mechanism of this compound. By subcellular imaging, we demonstrate a rapid cellular uptake of the conjugate and accumulation in the endoplasmic reticulum (ER). This localization is connected to induction of Ca2+ release from the ER into the cytosol. Depletion of Ca2+ from the ER induces the unfolded protein response as shown by global mRNA analysis and Western blot analysis of proteins in the pathway. In particular, salinomycin-induced ER Ca2+ depletion up-regulates C/EBP homologous protein (CHOP), which inhibits Wnt signaling by down-regulating β-catenin. The increased cytosolic Ca2+ also activates protein kinase C, which has been shown to inhibit Wnt signaling. These results reveal that salinomycin acts in the ER membrane of breast cancer cells to cause enhanced Ca2+ release into the cytosol, presumably by mediating a counter-flux of K+ ions. The clarified mechanistic picture highlights the importance of ion fluxes in the ER as an entry to inducing phenotypic effects and should facilitate rational development of cancer treatments.

Entities:  

Year:  2018        PMID: 29974072      PMCID: PMC6026786          DOI: 10.1021/acscentsci.8b00257

Source DB:  PubMed          Journal:  ACS Cent Sci        ISSN: 2374-7943            Impact factor:   14.553


Introduction

Phenotypic heterogeneity within tumors presents a significant obstacle toward curative cancer treatment.[1] Extensive efforts have therefore been directed at new therapies to eliminate subpopulations of cancer cells with stem-cell-like properties, as these are linked to recurrence and metastasis.[2,3] Stemlike cancer cells are particularly problematic as they exhibit up-regulated cellular defense mechanisms and are less susceptible to chemotherapy treatment.[4] In 2009, the natural product salinomycin was shown by Gupta et al. to have promise in this regard.[2] Salinomycin efficiently and selectively reduced the proportion of breast cancer CD44+/CD24– cells, a phenotype associated with enhanced tumorigenic capacity.[2,5] Importantly, pretreatment of cancer cells with salinomycin was also shown to reduce tumor-initiating capacity in animal models. Since the original report, salinomycin has shown activity across numerous cancer cell lines of varying origins.[6] Mechanistically, effects on several signal transduction pathways have been invoked to explain the change in phenotype composition after salinomycin treatment. Importantly, Lu et al. showed that salinomycin treatment inhibits the Wnt signaling pathway, a pathway involved in tumorigenesis and embryogenesis, through more than one mechanism.[7] Other pathways inhibited by salinomycin include K-Ras[8] and Hedgehog signaling.[9] However, the molecular origin of the phenotypic effects is unclear, and the mechanistic picture is obscured by the diversity of cellular responses to salinomycin treatment, especially when high μM concentrations are used. Demonstrated effects of salinomycin treatment include impaired mitochondrial function, induction of autophagy, decreased ATP levels, increased reactive oxygen species (ROS) production,[10−13] and a recent study suggested sequestration of iron in lysosomes.[14] In addition, salinomycin treatment has been shown to induce ER (endoplasmic reticulum) stress in different cell lines.[15,16] ER stress is a cellular defense mechanism that can force epithelial stem cells[17] and stemlike cancer cells to differentiate.[18,19] It is known that this response can be induced by depletion of the ER Ca2+ stores,[20] and increases in cytosolic Ca2+ have been observed following salinomycin treatment.[10,21] Functionally, salinomycin is a K+-selective ionophore, and accumulating evidence points to its ion transport properties as the origin of phenotype effects.[22−25] However, the molecular basis of the changes in phenotype composition, i.e., which ion fluxes in the cell are mediated by salinomycin to induce phenotype effects, is unknown. We reasoned that the action of a small molecule ionophore like salinomycin should be connected to the membrane(s) into which it is inserted, and therefore that subcellular imaging of a fluorescent analog would help to elucidate the basis of its activity. Here, we report a mechanistic investigation of the molecular origin of the phenotype effects of salinomycin guided by subcellular localization of a fluorescent salinomycin conjugate that retains the biological profile of salinomycin. For this purpose, we utilized synthetic methodologies previously developed in our laboratories for synthesis of improved semisynthetic analogs.[23] We show that the conjugate exhibits a rapid cellular uptake in breast cancer cells and a pronounced accumulation in the endoplasmic reticulum (ER) and lipid droplets (LDs). Furthermore, the ER is shown to be the intracellular source of the increased cytosolic Ca2+ resulting from salinomycin treatment. Depletion of Ca2+ in the ER lumen causes ER stress and up-regulation of C/EBP homologous protein (CHOP), which is a known Wnt signaling inhibitor.[26] In addition, the concomitant increase in cytosolic Ca2+ activates protein kinase C (PKC), which too is an inhibitor of Wnt signaling.[27,28] Moreover, the canonical Wnt/LRP6-mediated signaling pathway is impeded by increased Ca2+ levels.[29] Importantly, these data provide a connection between the ionophoric activity of salinomycin in the ER and previously described changes in phenotype composition via inhibition of Wnt signaling.[30]

Results

Synthesis and Cellular Uptake of Fluorescent Salinomycin Conjugates

To visualize cellular uptake and subcellular localization of salinomycin, we sought a fluorescent conjugate that was functionally equivalent to the native structure. Selective ligation of fluorophores to complex natural products like salinomycin without impairing their properties is nontrivial. A fluorescein derivative of okadic acid ligated at the carboxylate position which is vital to activity[31] was reported by Sandler et al.,[32] but no fluorescent polyether ionophore conjugate shown to retain activity is known. Whitehouse’s nitrobenzoxadiazole (NBD) reporter[33] has previously found use for labeling steroids and phospholipids because of its strong fluorescence in hydrophobic environments.[34] It has also been used for uptake studies of amino sugars in mammalian cells.[35] We reasoned that the comparatively small size, lack of reactivity (bio-orthogonality), and low polarity of the NBD suggested that it might also be a suitable reporter for subcellular imaging of complex polyoxygenated natural products like salinomycin. We therefore devised a conjugate of salinomycin bearing an NBD reporter ligated at the C20-hydroxyl group (Figure ). Esterification at this position was shown by Miazaki et al. to enhance the antibiotic activity.[36] We recently demonstrated that salinomycin derivatives such as ethyl carbonate 3 with modifications to this position exhibit both increased basal toxicity and enhanced activity against breast cancer stem cells.[24,25]
Figure 1

Design and synthesis of the fluorescent salinomycin NBD conjugates 6 and 7. brsm = based on recovered starting material.

Design and synthesis of the fluorescent salinomycin NBD conjugates 6 and 7. brsm = based on recovered starting material. Synthetically, the readily available alcohol 5(37) was reacted with phosgene in pyridine and subsequently with ester 4 in a one-pot procedure to give the corresponding carbonate with a complete selectivity for the C20-hydroxyl group. A fluoride-mediated deprotection of the carboxyl group then provided the targeted conjugate 6, which merged the activity-enhancing structural features of ethyl carbonate 3 with the fluorescent NBD moiety. As a negative control, methyl ester 7, which is incapable of electroneutral alkali metal ion transport, was similarly prepared. The stability of the conjugates was corroborated by treatment with a large excess of the nucleophile glutathione in d6-dimethyl sulfoxide at room temperature. No decomposition was observed by 1H NMR spectroscopy under these conditions, even after several days. Conjugate 6 was found to be functionally equivalent to salinomycin when evaluated in the JIMT-1 breast cancer cell line, with respect to both basal toxicity and phenotype selectivity. An MTT-based assay showed an IC50 of 0.36 ± 0.04 μM (Figure A), which is comparable to that of salinomycin (IC50 = 0.52 μM).[23] The methyl ester 7 was shown to be over 2 orders of magnitude less active than salinomycin in this assay. Significantly, conjugate 6 was found equally effective as salinomycin in reducing Wnt signaling, when evaluated both in a Wnt reporter cell line (Figure B) and in TOPFlash-transfected JIMT-1 cells (Figure C). Conjugate 7 was inactive in these assays, and the compounds did not show FOPFlash activity in transfected JIMT-1 cells (Figure S4). Pretreatment of JIMT-1 cells with 6 at IC50 also gave a reduction in colony-forming efficiency (CFE) in serum-free medium by ∼50% compared to control (Figure D). At the protein level, treatment of JIMT-1 cells with 6 gave a similar reduction in the levels of active β-catenin, low-density lipoprotein receptor-related protein 6 (LRP6), and phospho-LRP6 (p-LRP6) as salinomycin (Figure E).
Figure 2

Biological activity of conjugates 6 and 7. (A) Dose response curves and IC50 (mean ± SE, n = 3) of conjugates 6 (black) and 7 (gray) in JIMT-1 cells obtained using an MTT-based assay. (B) Wnt/β-catenin luciferase reporter assay in Leading Light Wnt reporter cells. Columns show mean ± SE (n = 8). DMSO control = 100%. Cells were treated for 24 h. Firefly luciferase levels were normalized to Renilla luciferase levels. (C) Wnt/β-catenin luciferase reporter assay in JIMT-1 cells transfected with TOPFlash and Renilla plasmids. Cells were treated for 24 h. Columns show mean ± SE (n = 3). DMSO control = 100%. Firefly luciferase levels were normalized to Renilla luciferase levels. (D) Colony-forming efficiency (CFE) of JIMT-1 cells following treatment with conjugate 6 at IC50 (0.36 μM) for 72 h. Reported as percentage of colonies formed compared to DMSO control. Columns show mean ± SE (n = 3). (E) Inhibition of Wnt/β-catenin signaling in JIMT-1 cells. Cells were treated with the indicated concentrations for 72 h. Representative Western blots (n ≥ 3) used for densitometric scanning. SA, salinomycin (1). **P < 0.01; ***P < 0.001; ns, not significant.

Biological activity of conjugates 6 and 7. (A) Dose response curves and IC50 (mean ± SE, n = 3) of conjugates 6 (black) and 7 (gray) in JIMT-1 cells obtained using an MTT-based assay. (B) Wnt/β-catenin luciferase reporter assay in Leading Light Wnt reporter cells. Columns show mean ± SE (n = 8). DMSO control = 100%. Cells were treated for 24 h. Firefly luciferase levels were normalized to Renilla luciferase levels. (C) Wnt/β-catenin luciferase reporter assay in JIMT-1 cells transfected with TOPFlash and Renilla plasmids. Cells were treated for 24 h. Columns show mean ± SE (n = 3). DMSO control = 100%. Firefly luciferase levels were normalized to Renilla luciferase levels. (D) Colony-forming efficiency (CFE) of JIMT-1 cells following treatment with conjugate 6 at IC50 (0.36 μM) for 72 h. Reported as percentage of colonies formed compared to DMSO control. Columns show mean ± SE (n = 3). (E) Inhibition of Wnt/β-catenin signaling in JIMT-1 cells. Cells were treated with the indicated concentrations for 72 h. Representative Western blots (n ≥ 3) used for densitometric scanning. SA, salinomycin (1). **P < 0.01; ***P < 0.001; ns, not significant. Conjugate fluorescence was measured with time-resolved fluorescence microscopy imaging using the experimental setup illustrated in Figure A.[38] The fluorescence properties of N,N-dialkyl NBD’s are reported to be highly sensitive to the local environment;[39] however, both conjugates 6 and 7 exhibited quite high fluorescence quantum yield enabling fluorescence imaging of cells containing these molecules. The active conjugate 6 emitted green light in JIMT-1 cells with a λmax of 535 nm. The fluorescence lifetimes of conjugate 6 were similar in different parts of the cell (the bright spots and the less bright regions visible in the images), indicating that fluorescence quantum yields are not very sensitive to differences in cellular environments. In quantitative terms, the fluorescence lifetime was on average 2.1 times longer in cells than in the surrounding buffer solution, and 1.7 times longer in cells than in pure DMSO (Figure B, and Figures S1 and S2). In practice this means that the ratio of concentration of 6 in the cell and in buffer is approximately equal to the difference in observed brightness divided by a factor of 2 (the ratio of the lifetimes). Fluorescence can therefore be used to assess the localization of conjugate 6, both within and outside of the cell.
Figure 3

Cellular uptake and spectroscopic properties of conjugates. (A) Fluorescence microscopy experimental setup. (B) Fluorescence decay of conjugate 6 in various environments: ⟨τ⟩amp: cell = 2.7 ns; buffer = 1.2 ns; DMSO = 1.6 ns. (C) Representative data for real-time accumulation of conjugates 6 (black) and 7 (gray) (20 μM in HBSS with 2% DMSO) in individual JIMT-1 cells as monitored by fluorescence intensity. Fluorescence intensity flashes originating from aggregates of 7 during image capture (seen as gaps in the curve) were removed for clarity. (D) Fluorescence images of representative individual cells recorded during real-time accumulation experiments of conjugate 6 and 7. Scale bar = 20 μm.

Cellular uptake and spectroscopic properties of conjugates. (A) Fluorescence microscopy experimental setup. (B) Fluorescence decay of conjugate 6 in various environments: ⟨τ⟩amp: cell = 2.7 ns; buffer = 1.2 ns; DMSO = 1.6 ns. (C) Representative data for real-time accumulation of conjugates 6 (black) and 7 (gray) (20 μM in HBSS with 2% DMSO) in individual JIMT-1 cells as monitored by fluorescence intensity. Fluorescence intensity flashes originating from aggregates of 7 during image capture (seen as gaps in the curve) were removed for clarity. (D) Fluorescence images of representative individual cells recorded during real-time accumulation experiments of conjugate 6 and 7. Scale bar = 20 μm. The fluorescence microscope also allowed us to monitor the cellular uptake of conjugate 6 and 7 in real time in individual JIMT-1 cells cultured on a microscope coverslip. Prior to addition of compound, an isolated cell covered in buffer was selected for imaging. At time zero, a Hank’s balanced salt solution (HBSS) of conjugate 6 or 7 was added to the buffer outside of the irradiated area, and fluorescence images were continuously recorded with 0.1 s time resolution. Following addition, the conjugate spread rapidly throughout the solution (<1 s), and accumulation in the cell was monitored as an increase in cell fluorescence (Figure C; Movie S1, Supporting Information). The time scale of uptake was found to be in the order of tens of seconds, as illustrated by sequences of fluorescence images (Figure D and Figure S3). Figure C shows how the fluorescence intensity inside and outside the cell is evolving after addition of the conjugates. After approximately 1 min, the fluorescence intensity density in the cells became at least 100 times larger than that in the surrounding buffer indicating strong and rapid accumulation of the conjugates in the cell. This shows a fast passage across the plasma membrane of JIMT-1 cells for both conjugates 6 and 7, and by extension, for salinomycin itself. Thus, we demonstrated that ligation of an NBD reporter to the C20 hydroxyl of salinomycin gives a fluorescent conjugate that is functionally equivalent to salinomycin and hence suitable for mechanistic investigations. The real-time uptake experiments moreover revealed salinomycin derivatives entering cells on a time scale that supports using such structures for acute cell experiments.

Salinomycin Accumulates in the Endoplasmic Reticulum and in Lipid Droplets

The subcellular localization of salinomycin conjugates in breast cancer cells was investigated using confocal microscopy. Cells treated with a 2 μM solution of conjugate 6 showed a rapid perinuclear accumulation of fluorescence together with the appearance of brightly fluorescent spots (Figure A). Costaining with ER-Tracker Red revealed strong colocalization of 6 within the ER in three breast cancer cell lines: JIMT-1, MCF-7, and HCC1937 (Figure A and Figure S5A).
Figure 4

Imaging of fluorescent conjugate 6 in three breast cancer cell lines. Confocal and epifluorescence microscopy was carried out on JIMT-1, MCF-7, and HCC1937 cell lines. (A) Colocalization with ER-Tracker Red. Colocalization shown in orange/yellow. (B) Colocalization with Nile Red in LDs. The cells were incubated with Nile Red and images captured. The Nile Red was then bleached until no fluorescence was observed. Compound 6 was added to the medium of the cells, and images were captured ∼10 min after the imaging of Nile Red. (C, D) Absence of colocalization with Rhodamine 123 in mitochondria. The cells were incubated with Rhodamine 123, and images were captured. The Rhodamine 123 was then bleached until no fluorescence was observed. Compound 6 was added to the medium of the cells, and images were captured ∼10 min after imaging of Rhodamine 123. Panels C and D show maximum intensity projections and single optical planes, respectively. All images in panels A–D were obtained with a laser scanning confocal microscope. Scale bars = 10 μm. (E) DIC and fluorescence images of conjugate 6 in the three breast cancer cell lines were obtained with an epifluorescence microscope. Scale bar = 20 μm.

Imaging of fluorescent conjugate 6 in three breast cancer cell lines. Confocal and epifluorescence microscopy was carried out on JIMT-1, MCF-7, and HCC1937 cell lines. (A) Colocalization with ER-Tracker Red. Colocalization shown in orange/yellow. (B) Colocalization with Nile Red in LDs. The cells were incubated with Nile Red and images captured. The Nile Red was then bleached until no fluorescence was observed. Compound 6 was added to the medium of the cells, and images were captured ∼10 min after the imaging of Nile Red. (C, D) Absence of colocalization with Rhodamine 123 in mitochondria. The cells were incubated with Rhodamine 123, and images were captured. The Rhodamine 123 was then bleached until no fluorescence was observed. Compound 6 was added to the medium of the cells, and images were captured ∼10 min after imaging of Rhodamine 123. Panels C and D show maximum intensity projections and single optical planes, respectively. All images in panels A–D were obtained with a laser scanning confocal microscope. Scale bars = 10 μm. (E) DIC and fluorescence images of conjugate 6 in the three breast cancer cell lines were obtained with an epifluorescence microscope. Scale bar = 20 μm. Imaging of LDs by staining with Nile Red, followed by bleaching and subsequent addition of conjugate 6, revealed a highly similar pattern of bright spots suggesting the presence of 6 also within LDs (Figure B and Figure S6). Minor movement of cells and LDs during the course of the experiment explains why the patterns are not fully superimposable. Differential interference contrast (DIC) images of cells treated with conjugate 6 further corroborated the distribution to the ER and LDs (Figure E and Figure S9). The nonactive conjugate 7 showed a similar distribution in cells (Figures S5B and S8). The effect of salinomycin on cells has generally been associated with interference of mitochondrial function.[10,40] Since mitochondria and ER have a similar distribution in cells, we also investigated if salinomycin localized to mitochondria. Imaging of mitochondria in JIMT-1 cells incubated with the mitochondrial stain Rhodamine 123, followed by bleaching and subsequent addition of conjugate 6, revealed markedly different patterns of staining which indicated a low mitochondrial localization (Figure C,D and Figure S7). LDs are lipophilic structures that originate from lipid deposits in the ER phospholipid bilayer and thus share many of its characteristics.[41] We interpret the preferential accumulation of the conjugates in the ER and LDs as a reflection of their lipophilic nature. Combined with the observation that only salinomycin derivatives capable of electroneutral alkali metal ion transport induces phenotype effects,[42] the localization data indicate that the principal function of salinomycin is ionophore activity in the ER membrane.

Salinomycin Induces ER Ca2+ Release, ER Stress, and PKC Activation

Accumulation of salinomycin in the ER suggests that its ion transport properties may underlie its effect on the cytosolic Ca2+ concentration. The Ca2+ source contributing to the increase in cytosolic Ca2+ caused by salinomycin was thus investigated. JIMT-1 cells were incubated with and without Ca2+ added to the buffer and then treated with 2 μM salinomycin. Significant increases in cytosolic Ca2+ compared to control were found within 10 min in both cases. This implies that the increase originates, at least in part, from intracellular Ca2+ stores (Figure A). Elevated levels of cytosolic Ca2+ were found also after 72 h of treatment (Figure B). We also investigated the effects on Ca2+ release of a more active analog, ethyl carbonate 3 (Figure B). It is noteworthy that carbonate 3 elicited a similar response as salinomycin already at 1/10 of the dose in this assay.
Figure 5

Salinomycin treatment increases cytosolic Ca2+ and induces ER stress. (A) Acute salinomycin treatment induced Ca2+ release from ER. JIMT-1 cells were labeled with Fluo-4 AM and imaged with confocal microscopy. Salinomycin or salinomycin methyl ester 2 was added at a 2 μM concentration in Ca2+-containing or Ca2+-free medium. Ca2+ release channels in the ER membrane were blocked with 100 μM ryanodine and 50 μM 2-APB before the addition of salinomycin. Data shown are mean ± SE (n = 4). (B) Salinomycin or salinomycin 20-ethyl carbonate 3 treatment increased cytosolic Ca2+. After 72 h of treatment at indicated concentrations, cells were stained with Fluo-3 AM and analyzed with flow cytometry. The relative fluorescence intensity representing the Ca2+ level in the cytosol was calculated. Data shown are mean ± SE (n = 4). (C) Increased PKC activity in cells treated with 0.5 μM salinomycin for 72 h. Data shown are mean ± SE (n ≥ 4). (D) Supervised hierarchical clustering of differentially expressed genes in JIMT-1 cells treated with 50 nM salinomycin or salinomycin 20-ethyl carbonate 3 for 72 h (n = 6). SAM analysis was performed to identify differentially expressed genes between the groups. Genes with q-value ≤1 and an absolute fold change ≥2 were considered to be significantly differentially expressed. Red represents relative up-regulation, and green represents relative down-regulation. (E) Top significantly enriched biological processes up-regulated in carbonate 3-treated cells. Gene ontology (GO) enrichment analysis was performed using the AmiGO database. (F) Activation of the ATF6α pathway by salinomycin or inactive salinomycin methyl ester 2 treatment in JIMT-1 and MCF-7 cells. Cells were treated with the indicated concentrations for 72 h. Representative Western blots (n = 4) used for densitometric scanning showing the expression of UPR-related proteins. SA, salinomycin (1). (G) CHOP-siRNA-treated JIMT-1 cells reduce the level of active β-catenin upon salinomycin treatment. Cells were transfected with CHOP-siRNA and scramble siRNA for 72 h, followed by treatment with salinomycin (5 μM) for 72 h. Representative Western blots (n ≥ 4) used for densitometric scanning showing the expression of active β-catenin and CHOP. SA, salinomycin (1). *P < 0.05; **P < 0.01; ***P < 0.001.

Salinomycin treatment increases cytosolic Ca2+ and induces ER stress. (A) Acute salinomycin treatment induced Ca2+ release from ER. JIMT-1 cells were labeled with Fluo-4 AM and imaged with confocal microscopy. Salinomycin or salinomycin methyl ester 2 was added at a 2 μM concentration in Ca2+-containing or Ca2+-free medium. Ca2+ release channels in the ER membrane were blocked with 100 μM ryanodine and 50 μM 2-APB before the addition of salinomycin. Data shown are mean ± SE (n = 4). (B) Salinomycin or salinomycin 20-ethyl carbonate 3 treatment increased cytosolic Ca2+. After 72 h of treatment at indicated concentrations, cells were stained with Fluo-3 AM and analyzed with flow cytometry. The relative fluorescence intensity representing the Ca2+ level in the cytosol was calculated. Data shown are mean ± SE (n = 4). (C) Increased PKC activity in cells treated with 0.5 μM salinomycin for 72 h. Data shown are mean ± SE (n ≥ 4). (D) Supervised hierarchical clustering of differentially expressed genes in JIMT-1 cells treated with 50 nM salinomycin or salinomycin 20-ethyl carbonate 3 for 72 h (n = 6). SAM analysis was performed to identify differentially expressed genes between the groups. Genes with q-value ≤1 and an absolute fold change ≥2 were considered to be significantly differentially expressed. Red represents relative up-regulation, and green represents relative down-regulation. (E) Top significantly enriched biological processes up-regulated in carbonate 3-treated cells. Gene ontology (GO) enrichment analysis was performed using the AmiGO database. (F) Activation of the ATF6α pathway by salinomycin or inactive salinomycin methyl ester 2 treatment in JIMT-1 and MCF-7 cells. Cells were treated with the indicated concentrations for 72 h. Representative Western blots (n = 4) used for densitometric scanning showing the expression of UPR-related proteins. SA, salinomycin (1). (G) CHOP-siRNA-treated JIMT-1 cells reduce the level of active β-catenin upon salinomycin treatment. Cells were transfected with CHOP-siRNA and scramble siRNA for 72 h, followed by treatment with salinomycin (5 μM) for 72 h. Representative Western blots (n ≥ 4) used for densitometric scanning showing the expression of active β-catenin and CHOP. SA, salinomycin (1). *P < 0.05; **P < 0.01; ***P < 0.001. For verification of whether the ER was a significant contributor to the increase in cytosolic Ca2+, the ER Ca2+ release channels, inositol trisphosphate receptor (IP3R) and ryanodine receptor (RyR), were simultaneously inhibited by a combination of 2-aminoethoxydiphenyl borate (2-APB) and ryanodine, respectively. In this experiment, no increase in cytosolic Ca2+ compared to control was seen after treatment with salinomycin which supports that the ER is indeed the primary intracellular source of released Ca2+ (Figure A). As expected, methyl ester 2 had no effect on cytosolic Ca2+ concentration in JIMT-1 cells (Figure A). Treatment with ER Ca2+ channel blockers prior to salinomycin treatment gave small changes in the cytosolic Ca2+ level. This suggests that salinomycin-mediated Ca2+ release from other intracellular stores such as mitochondria was small. In agreement with this, no increase in cytosolic Ca2+ was found following salinomycin treatment after depletion of ER calcium by thapsigargin (Figure S10). This suggests that the mitochondrial effects following treatment with salinomycin are secondary effects to increased cytosolic Ca2+. This causes uptake of Ca2+ into the mitochondria with decreased mitochondrial membrane potential and reduced ATP production as a result. For a broader view of the changes in gene activity following salinomycin treatment, a global mRNA analysis of JIMT-1 cells after treatment with 50 nM of salinomycin or ethyl carbonate 3 was performed. In all, 273 differentially expressed genes were found (Data Set S1). Strikingly, there were a high number of hits with low P-values for genes in pathways involved in the unfolded protein response (UPR) (Figure D,E; Data Set S2). In particular, the 78 kDa glucose-regulated protein (GRP78) was significantly up-regulated at the mRNA level (Figure E). Increased expression of this protein was also confirmed in both JIMT-1 and MCF-7 cells by Western blot analysis (Figure F). Increased GRP78 is important for maintaining cell viability against several kinds of stress including depletion of Ca2+ from the ER.[20,43] The gene DNA damage inducible transcript 3 (DDIT3) encoding for CHOP was also significantly up-regulated at the mRNA level in cells treated with carbonate 3 (Figure E). CHOP is a multifunctional transcription factor in the ER-stress response and is known to inhibit the Wnt/β-catenin signaling pathway.[26] At the protein level, only a weak activation of CHOP was seen; however, CHOP is most efficiently increased when both the protein kinase RNA-like endoplasmic reticulum kinase (PERK) and activating transcription factor 6 (ATF6) pathways are activated.[44] We found activation of ATF6 (Figure F) in treated cells but not of PERK or inositol-requiring enzyme (IRE1) (Figure S11), which may explain the small increase in CHOP. These three ER-stress sensors are not always activated in consort during ER stress, and different conditions are known to result in differing patterns of activation.[45] As shown in Figure C, salinomycin treatment decreased the expression of active β-catenin, but the total β-catenin level was not significantly changed. In cells where CHOP was knocked down by transfection with CHOP-siRNA, salinomycin treatment gave a lower reduction of active β-catenin compared to cells transfected with scrambled siRNA (Figure G). These results support that up-regulation of CHOP following salinomycin treatment contributes to inhibition of the Wnt signaling pathway. The increase in cytosolic Ca2+ is also important for a description of the mechanism of salinomycin. Ca2+ is a vital second messenger that activates conventional (calcium-dependent) PKCs[46] to further inhibit the canonical Wnt/β-catenin pathway.[28] In line with this, we found that treatment of JIMT-1 cells with salinomycin promotes a significant activation of PKC (Figure C). Combined, the data show that salinomycin causes an increase in the release of Ca2+ from the ER. This release ultimately results in an increase in CHOP expression and activation of calcium-dependent PKC, both known factors contributing to inhibition of Wnt signaling.

Discussion

Salinomycin treatment is known to reduce the proportion of stemlike cancer cells in a cancer cell population via inhibition of the Wnt signaling pathway, but the molecular basis of this effect is unclear. The work described here reveals Ca2+ release from the ER into the cytosol as the molecular initiating event. Our interpretation of the mode of action in the ER is that it derives from a salinomycin-mediated net influx of K+ from the cytosol to the ER lumen (Figure ). Both release and uptake of Ca2+ into the ER is contingent on a counter-flux of K+ to retain charge-neutrality.[47] A K+-selective ionophore like salinomycin, localized in the ER membrane and acting as a passive potassiumhydrogen exchanger, can thus in principle facilitate both uptake and release of Ca2+.
Figure 6

Schematic representation of the proposed mechanism for Wnt/β-catenin inhibition by salinomycin.

Schematic representation of the proposed mechanism for Wnt/β-catenin inhibition by salinomycin. In accordance, nigericin, which is a functionally and structurally related K+-selective polyether ionophore, has previously been shown to both reverse apamin blockage of IP3-mediated Ca2+ release from the ER[47] and attenuate propranolol inhibition of Ca2+ reuptake.[48,49] Ionophore-mediated K+ flux into the ER also connects to Ca2+ release by causing decomplexation of protein-bound Ca2+ in the ER via K+/Ca2+ exchange. This accentuates Ca2+ release, since increased ER Ca2+ levels are the trigger of Ca2+-induced Ca2+ release.[47,50] We thus attribute the increase in cytosolic Ca2+ to a promoted release of Ca2+ from the ER, rather than to an impeded reuptake. In summary, we developed a fluorescent NBD conjugate of salinomycin that retains the activity profile of the native structure. This conjugate was used to guide a mechanistic investigation of the molecular basis for the activity of salinomycin against stemlike cancer cells. The conjugate was shown to rapidly enter breast cancer cells and localize in the ER and LDs. Uptake of salinomycin into the ER was then shown to result in an enhanced Ca2+ release from this organelle, presumably a result of a counter transport of K+ by salinomycin. Depletion of Ca2+ from the ER led to ER stress and activation of the UPR, which induced up-regulation of CHOP. The concomitant increase in cytosolic Ca2+ caused activation of conventional PKCs. Since both up-regulation of CHOP and activation of PKC inhibit the Wnt signaling pathway, our work connects the mechanism of salinomycin at the molecular level to previously described phenotype effects. Finally, we anticipate that the simplicity of selective carbonate ligation of NBD fluorophores paired with the favorable chemical, biological, and photophysical properties of such conjugates should find wider use in imaging cellular uptake and mechanistic studies, in the context of both natural products and other complex molecules. In a broader sense, the results of this mechanistic study emphasize the potential importance of K+ flux across the ER membrane as a prospective mechanism to induce and study phenotype effects in cancer cells and possibly also in other cell types.
  46 in total

1.  The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals.

Authors:  M Horndasch; S Lienkamp; E Springer; A Schmitt; H Pavenstädt; G Walz; J Gloy
Journal:  Oncogene       Date:  2006-01-23       Impact factor: 9.867

2.  Structure-Activity Relationships in Salinomycin: Cytotoxicity and Phenotype Selectivity of Semi-synthetic Derivatives.

Authors:  Björn Borgström; Xiaoli Huang; Cecilia Hegardt; Stina Oredsson; Daniel Strand
Journal:  Chemistry       Date:  2016-11-17       Impact factor: 5.236

3.  Salinomycin Hydroxamic Acids: Synthesis, Structure, and Biological Activity of Polyether Ionophore Hybrids.

Authors:  Björn Borgström; Xiaoli Huang; Eduard Chygorin; Stina Oredsson; Daniel Strand
Journal:  ACS Med Chem Lett       Date:  2016-04-25       Impact factor: 4.345

Review 4.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 5.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 6.  Protein kinase C in Wnt signaling: implications in cancer initiation and progression.

Authors:  Luis Bernardo Luna-Ulloa; José G Hernández-Maqueda; M Cristina Castañeda-Patlán; Martha Robles-Flores
Journal:  IUBMB Life       Date:  2011-09-09       Impact factor: 3.885

7.  Selective activation of the transcription factor ATF6 mediates endoplasmic reticulum proliferation triggered by a membrane protein.

Authors:  Jessica Maiuolo; Stefania Bulotta; Claudia Verderio; Roberta Benfante; Nica Borgese
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-26       Impact factor: 11.205

Review 8.  Polyether ionophores-promising bioactive molecules for cancer therapy.

Authors:  Adam Huczyński
Journal:  Bioorg Med Chem Lett       Date:  2012-09-23       Impact factor: 2.823

Review 9.  Salinomycin as a drug for targeting human cancer stem cells.

Authors:  Cord Naujokat; Roman Steinhart
Journal:  J Biomed Biotechnol       Date:  2012-11-21

10.  Early effects of the antineoplastic agent salinomycin on mitochondrial function.

Authors:  A Managò; L Leanza; L Carraretto; N Sassi; S Grancara; R Quintana-Cabrera; V Trimarco; A Toninello; L Scorrano; L Trentin; G Semenzato; E Gulbins; M Zoratti; I Szabò
Journal:  Cell Death Dis       Date:  2015-10-22       Impact factor: 8.469

View more
  16 in total

1.  Gramicidin A accumulates in mitochondria, reduces ATP levels, induces mitophagy, and inhibits cancer cell growth.

Authors:  Yun-Wei Xue; Hiroaki Itoh; Shingo Dan; Masayuki Inoue
Journal:  Chem Sci       Date:  2022-06-03       Impact factor: 9.969

2.  Expeditive Synthesis of Potent C20-epi-Amino Derivatives of Salinomycin against Cancer Stem-Like Cells.

Authors:  Dominika Czerwonka; Sebastian Müller; Tatiana Cañeque; Ludovic Colombeau; Adam Huczyński; Michał Antoszczak; Raphaël Rodriguez
Journal:  ACS Org Inorg Au       Date:  2022-01-05

3.  Salinomycin inhibits epigenetic modulator EZH2 to enhance death receptors in colon cancer stem cells.

Authors:  Anup Kumar Singh; Ayushi Verma; Akhilesh Singh; Rakesh Kumar Arya; Shrankhla Maheshwari; Priyank Chaturvedi; Mushtaq Ahmad Nengroo; Krishan Kumar Saini; Achchhe Lal Vishwakarma; Kavita Singh; Jayanta Sarkar; Dipak Datta
Journal:  Epigenetics       Date:  2020-07-08       Impact factor: 4.528

4.  Effects of salinomycin and niclosamide on small cell lung cancer and small cell lung cancer circulating tumor cell lines.

Authors:  Maximilian Hochmair; Barbara Rath; Lukas Klameth; Ernst Ulsperger; Christoph Weinlinger; Andreas Fazekas; Adelina Plangger; Robert Zeillinger; Gerhard Hamilton
Journal:  Invest New Drugs       Date:  2019-08-24       Impact factor: 3.850

Review 5.  Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.

Authors:  Vivek Kaushik; Juan Sebastian Yakisich; Anil Kumar; Neelam Azad; Anand K V Iyer
Journal:  Cancers (Basel)       Date:  2018-09-27       Impact factor: 6.639

6.  Extracellular and intracellular small-molecule galectin-3 inhibitors.

Authors:  John Stegmayr; Fredrik Zetterberg; Michael C Carlsson; Xiaoli Huang; Gunjan Sharma; Barbro Kahl-Knutson; Hans Schambye; Ulf J Nilsson; Stina Oredsson; Hakon Leffler
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

7.  Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model.

Authors:  Johannes Klose; Stefan Trefz; Tobias Wagner; Luca Steffen; Arsalie Preißendörfer Charrier; Praveen Radhakrishnan; Claudia Volz; Thomas Schmidt; Alexis Ulrich; Sebastian M Dieter; Claudia Ball; Hanno Glimm; Martin Schneider
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

8.  Enhanced and Prolonged Antitumor Effect of Salinomycin-Loaded Gelatinase-Responsive Nanoparticles via Targeted Drug Delivery and Inhibition of Cervical Cancer Stem Cells.

Authors:  Qin Wang; Fangcen Liu; Lifeng Wang; Chen Xie; Puyuan Wu; Shiyao Du; Shujuan Zhou; Zhichen Sun; Qin Liu; Lixia Yu; Baorui Liu; Rutian Li
Journal:  Int J Nanomedicine       Date:  2020-02-26

9.  Breast cancer cell line toxicity of a flavonoid isolated from Baccharis densiflora.

Authors:  Wendy Soria Sotillo; Santiago Tarqui; Xiaoli Huang; Giovanna Almanza; Stina Oredsson
Journal:  BMC Complement Med Ther       Date:  2021-07-02

10.  Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.

Authors:  Alicja Urbaniak; Megan R Reed; Daniel Fil; Anika Moorjani; Sarah Heflin; Michał Antoszczak; Michał Sulik; Adam Huczyński; Michalina Kupsik; Robert L Eoff; Melanie C MacNicol; Timothy C Chambers; Angus M MacNicol
Journal:  Biomed Pharmacother       Date:  2021-06-12       Impact factor: 7.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.